Skip to main content

Advertisement

Table 3 Comparing the sensory nerve conduction measurements between the two study groups

From: The effect of n-3 polyunsaturated fatty acids on incidence and severity of oxaliplatin induced peripheral neuropathy: a randomized controlled trial

  n-3 PUFAs (Mean ± SD) Placebo (Mean ± SD) Mean Difference 95 % CI P-value
Sural nerve     
aSAP1(μV) 9.95 (5.52–16.40) 5.50 (3.40–14.10) -- .033***
aSAP 2a 6.30 (4.60–10.30) .00 (.00–7.32)   .052b
%Changec − 36.68 − 100.00   
SCV1(m/s) 43.99 ± 15.17 44.82 ± 6.27 −.83 −6.44 to 4.78, .766*
SCV 2 42.29 ± 15.51 29.67 ± 13.01 12.24 2.22 to 22.26, .018**
% Change −3.84 − 33.80   
Ulnar nerve     
aSAP1(μV) 27.90 (16.82–42.77) 17.50 (12.40–35.50) -- .144***
a- SAP 2 22.80 (6.20–27.30) 10.14 (2.70–18.60)   .430b
% Change − 18.28 − 42.06   
SCV1(m/s) 51.66 ± 8.34 50.15 ± 8.23 1.50 −2.51 to 5.52, .457*
SCV 2 44.08 ± 11.14 42.62 ± 7.26 .98 −4.61 to 6.57, .726**
% Change − 14.66 − 15.01   
  1. a-SAP sensory action potential amplitude, SCV sensory conduction velocity
  2. *P value is reported based on Independent-Samples T-Test
  3. **P value is reported based on the analysis of covariance, adjusted for baseline values
  4. ***P value is reported based on the Mann–Whitney U Test
  5. aOne month after the cessation of chemotherapy
  6. b P value is reported based on the Mann–Whitney U Test (for changes of values during the intervention period)
  7. cPercent change in proportion to the baseline values